Skip to content

Structure-guided delineation of umbelliferyl phosphate-based disruptors of the c-Myb-CBP/p300 KIX protein-protein interaction.

Aug 2026 · Biophysical Chemistry · Vol 339, pp. 107704 · 0 citations · 38 references
Medicine

Abstract

The interaction between c-Myb and the CBP/p300 KIX domain is a critical transcriptional regulatory event and an attractive target for the development of candidate disruptors of the recombinant c-Myb-KIX interaction. In this study, we used an integrated computational and experimental strategy to identify new small molecules capable of disrupting this protein-protein interaction. A focused Umbelliferyl phosphate scaffold library was subjected to stepwise virtual screening via drug-likeness assessment and docking to the c-Myb-binding region of the KIX domain and short molecular dynamics refinement. Selected compounds were then evaluated by 500 ns molecular dynamics simulations, MM/PBSA analysis, free energy landscape (FEL) mapping, and finally by microscale thermophoresis (MST) assay. Computational analyses showed that stable ligand binding did not necessarily translate into disruption of the c-Myb-KIX interface, allowing separation of compounds that stabilized the complex from those predicted to weaken it. Consistent with this distinction, ΔΔGPPIanalysis identified only MUP and Naphthol AS-BI phosphate as protein-protein interaction-weakening ligands, with Naphthol AS-BI phosphate showing the strongest predicted disruptive effect (ΔΔGPPI=+3.25 kcal/mol), whereas DiFMUP and Naphthol AS-D phosphate were predicted to stabilize the complex. Among the tested molecules, Naphthol AS-BI phosphate showed the clearest disruption-like behavior in silico and was the most potent inhibitor in vitro, with an IC₅₀ of 18.9 ± 0.6 μM. Importantly, MUP emerged as the most promising umbelliferyl phosphate-derived hit, displaying measurable inhibitory activity (IC₅₀ = 33.5 ± 0.3 μM) comparable to the reference Naphthol AS-E phosphate (IC₅₀ = 31.2 ± 1.3 μM) and a more favorable predicted ADMET profile. Overall, this work identifies new chemical starting points for targeting the c-Myb-CBP/p300 KIX interaction and supports MUP as an attractive scaffold for further optimization.

View source

Similar papers

Open access Aug 2026

Structure‐Based Discovery of Fumiquinazolines as Skp2–Cks1 Protein–Protein Interaction Disruptors: Mechanistic Computational Insights and Experimental Validation

Findings identify Fumiquinazoline D as an early‐stage biochemical hit for disruption of the Skp2–Cks1 interaction and as a potential scaffold for further mechanistic validation and medicinal‐chemistry investigation.

Emadeldin M. Kamel, A. A. Allam, H. Rudayni et al. · 0 citations
Aug 2026

Targeting the c-Myb-CBP/p300 KIX protein-protein interaction with quinone-methide triterpenes: In silico mechanistic insights and MST biochemical validation.

Tingenone is identified as a promising scaffold for the development of new c-Myb-CBP/p300 KIX PPI inhibitors, having produced the clearest signatures of interfacial weakening and the most favorable disruption metrics.

Emadeldin M. Kamel, H. Rudayni, A. A. Allam et al. · 0 citations
Open access Aug 2026

Breaking the Myb–KIX Alliance: Structure‐Guided Discovery of Biaryl Hydroxy‐Naphthamides as Disruptors of the c‐Myb–CBP/p300 KIX Protein–Protein Interaction

3‐hydroxy‐2‐naphthamides are established as promising scaffolds for targeting the c‐Myb–CBP/p300 KIX interface and are supported as the most conformationally stable interfacial binders.

H. Alfassam, Emadeldin M. Kamel, Sarah I. Othman et al. · 0 citations
Open access Aug 2026

Pinoresinol as a Potential c-Myc Complex Modulator: An In Silico Study

In silico ADMET analysis predicted a high probability of cytotoxic inactivity and a favorable safety profile compared to traditional agents like vincristine, suggesting a protein–protein interface-oriented approach and position pinoresinol as a promising lead scaffold for disrupting c-Myc–associated transcriptional reg...

Arnulfo Villanueva-Castillo, Claudia Mancilla-Simbro, Fernando Villa-Diaz et al. · 0 citations
Open access Jul 2026

Designing novel adenine clamp-CD73 mutants delineating surface expression and enzyme activity through in silico and in vitro engineering.

Overexpression of CD73-F417V/F500V mutant in CD73 null-HEKs indicated stable surface expression but complete loss of Ecto-nucleotidase activity, thus providing a tool to dissect activity-dependent and independent functions of NT5E.

G. Mohan, Anaswara S Padmam, Anujith Kumar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.